US Recall News

United States Recall News Alerts for Recalled Drugs, Food, Products, & Vehicles

MENUMENU
  • Home
  • About
    • Advertise
  • Full Recall News Archive
    • Top Story

      J&J Settles Talc Mesothelioma Settlement

      By Sandra Dalton, Staff Writer On January 6, 2020, Superior Court Judge Stephen Kaus announced that Johnson & Johnsons (J&J) had agreed to … [Read More...]

      Casper’s Ice Cream Issues Allergy Alert on Mispackaged Red Button Canadian Vanilla Product Lot 344-21-946

      Summary Company Announcement Date: May 25, 2022 FDA Publish Date: May … [Read More...]

    • More Safety Articles
    • Federal Preemption of State Product Liability Law
  • Drug Recalls
    • Abilify
    • Benicar
    • Fluoroquinolones
    • Invokana
    • Lipitor
    • Nuplazid
    • Opioids
    • OxyContin
    • Pradaxa
    • Proton Pump Inhibitors (PPIs)
    • Risperdal
    • SSRI
    • Symptoms & Side Effects
    • Taxotere
    • Testosterone
    • Uloric
    • Valsartan
    • Xarelto
    • Zofran
  • Medical Devices
    • 3M Earplug
    • 3T Heater-Cooler System
    • Bair Hugger
    • Bipolar Hip System
    • Essure
    • Hip Replacements
    • Implanon
    • IVC Filters
    • Hernia Mesh
    • Power Morcellators
    • Shoulder Implants
    • Transvaginal Mesh
  • Food Recalls
    • FDA Press Releases
    • USDA Press Releases
  • Auto Recalls
    • Air Bags
    • Ignitions
    • NHTSA Press Releases
    • Off-Road Utility Vehicles
    • Snowmobiles
    • Tires
  • Other Products
    • Asbestos
    • Baby Products
    • Pet Products
    • Roundup
    • Talcum Powder
    • Toy Recalls
You are here: Home / Featured / J&J Spends Hundreds of Millions to Promote Xarelto, The Blood Thinner that Kills

J&J Spends Hundreds of Millions to Promote Xarelto, The Blood Thinner that Kills

October 7, 2015 By US Recall News Leave a Comment

The blood thinner market in the United States was worth over $8 billion in 2012 and is expected to grow to over $15 billion by 2018, according to a June 2013 report by pharmaceutical analysts EvaluatePharma. Xarelto, one of a new type of anti-coagulants that doesn’t require individual dosing (unlike category leader Warfarin) is big business for drug maker Johnson & Johnson with expected sales of over $1 billion a year.

Johnson & Johnson is consistently on a charm offensive with medical professionals, spending over $154 million in 2014 alone , according to the U.S Governments Open Payments Database, on outlays to Doctors. This includes wining and dining, speaker programs and consulting fees. An investigation by the New York Times in January 2015 showed that $19.3 million had been spent in the last five months of 2013 promoting just three anti-coagulant drugs to doctors (not all made by J&J).

Data from ProPublica reveals that Xarelto had $6.93 million spent on promoting it in the last five months of 2013, and a further $1.8 million spent on research payments directly related to it (4). It is also important to realize that despite these large payments that this data does not take into account amounts spent on the drug reps who visit the doctors, advertising to patients or doctors, or drug samples that are left for the doctors to try. Therefore, the real amount spent on promoting Xarelto is considerably higher.

It is with this backdrop of massive revenues and promotion budgets that the checkered safety history of Xarelto should be considered. The drug has only been approved by the FDA since 2011, but has already made significant in-roads into the territory of older-style blood thinners such as Warfarin, despite costing approximately 15 times more per year ($3,000 compared to $200 for Warfarin) in treatment costs.

The reasons for this are largely due to four factors that give Xarelto a perceived advantage, despite the high cost:

  1. Patients are not required to change their diet or alter their lifestyle.
  2. Regular checkups and monitoring are not felt to be needed.
  3. Risk of brain hemorrhage are reduced.
  4. Dosing is consistent and so much easier for the doctor to prescribe.

These four factors make prescribing Xarelto an easier sell to doctors, but there have already been rumblings coming out of the FDA about the safety of this new drug, despite it only having been available for a few years.

Xarelto was launched onto the drug market in a big way, but already there is mounting evidence of greater safety implications with the use of the drug then were first thought. Johnson & Johnson are keen to play down these fears, as one of the big selling points of this (expensive) drug to doctors is its supposed simplicity to prescribe and monitor. However, as the evidence mounts of these complications there is a distinct possibility that what is currently a rockslide of legal cases around the drug could very quickly become an avalanche.

Share this:

  • Facebook
  • Twitter
  • LinkedIn
  • Email
  • Print

Related

Filed Under: Featured, Xarelto Tagged With: Xarelto

About US Recall News

US Recall News provides recall news and information to the United States general public. Find all of the latest drug, food, products, and vehicle recall news as reported by U.S. government agencies and more.

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Facebook
Thomas Roney LLC
Economic Consulting

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Casper’s Ice Cream Issues Allergy Alert on Mispackaged Red Button Canadian Vanilla Product Lot 344-21-946

May 25, 2022 By The FDA

Brookshire Grocery Company Recalls Yellow Flesh Peaches Because of Possible Health Risk

May 25, 2022 By The FDA

BETA ( 22V325000 )

May 25, 2022 By NHTSA

Free Case Review

  • * = Required
    Privacy Policy
  • This field is for validation purposes and should be left unchanged.

Hero Highlight

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

GREAT DANE ( 22V328000 )

May 25, 2022 By NHTSA

UTILIMASTER ( 22V341000 )

May 25, 2022 By NHTSA

Coblentz Chocolate Company Recalls Select Peanut Butter Products Because of Possible Health Risk

May 24, 2022 By The FDA

Mary’s Harvest Fresh Foods, Inc. Issues Voluntary Recall of Celery Peanut Butter Cup G&G and Apple Peanut Butter Cup G&G Because of Possible Health Risk

May 24, 2022 By The FDA

Garden Cut, LLC Recalls Snack Cups Containing Jif® Peanut Butter Due to the Potential for Salmonella Contamination

May 24, 2022 By The FDA

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Mary’s Harvest Fresh Foods, Inc. Issues Voluntary Recall of Celery Peanut Butter Cup G&G and Apple Peanut Butter Cup G&G Because of Possible Health Risk

May 24, 2022 By The FDA

Garden Cut, LLC Recalls Snack Cups Containing Jif® Peanut Butter Due to the Potential for Salmonella Contamination

May 24, 2022 By The FDA

Fudgeamentals Recalls Fudge Made With Jif Peanut Butter Because of Possible Health Risk

May 24, 2022 By The FDA

Recall News in Your Inbox

Enter your email address to receive automated recall news updates.

Recent Comments

  • Roger McGowan on ABH NATURE’S PRODUCTS, INC, ABH PHARMA, INC., and STOCKNUTRA.COM, INC. Issues Nationwide Recall of All Lots of Dietary Supplement Products
  • Kathryn Moore on FDA Wants Cancer Warning on Breast Implants
  • BRAD on Huge ATV Recall by Polaris – Sportsman and Scrambler
  • Crystal Anderson on Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders
  • Outsourcing Training on The Modern Marketing of Pain
  • SANDRA Collett on Processed Food Preservative Linked to Autism?
  • Eric Karsh on Health Risks of Roundup Go Well Beyond Cancer

Recent Posts

  • Casper’s Ice Cream Issues Allergy Alert on Mispackaged Red Button Canadian Vanilla Product Lot 344-21-946
  • Brookshire Grocery Company Recalls Yellow Flesh Peaches Because of Possible Health Risk
  • BETA ( 22V325000 )
  • LUCID ( 22V351000 )
  • BLUE BIRD ( 22V330000 )
  • GREAT DANE ( 22V328000 )
  • UTILIMASTER ( 22V341000 )
  • Coblentz Chocolate Company Recalls Select Peanut Butter Products Because of Possible Health Risk
  • Mary’s Harvest Fresh Foods, Inc. Issues Voluntary Recall of Celery Peanut Butter Cup G&G and Apple Peanut Butter Cup G&G Because of Possible Health Risk
-- See More Recall News

Disclaimer: The information contained in these topics is not intended nor implied to be a substitute for professional medical or legal advice, it is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider about any questions you may have regarding a medical condition. Nothing contained in these topics is intended to be used for medical diagnosis or treatment.


ATTORNEY ADVERTISING. The information provided on this website is not legal advice. No attorney-client relationship is formed by the use of this site. It is not stated or implied that a lawyer is certified as a specialist in any particular field of law. No results are guaranteed, and prior results do not guarantee a similar outcome. This site is informational, only, not dispositive; it is up to you to decide whether a particular lawyer is right for you. Use of this site is subject to your agreement to these.


Copyright © 2022 Altrumedia · Terms of Service · Log in

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.